ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine ...

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine ...

We present PPTAgent, an innovative system that automatically generates presentations from documents. Drawing inspiration from human presentation creation methods, our system employs a two-step process ...

Objectives To describe the features and rates of emergency department (ED) presentations identified as related to violence against women (VAW) and of confirmed cases of family domestic violence (FDV) ...

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. ("Pharming” or "the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at ...

In May 2025, IMUNON announced positive six-month data from the Phase 1 trial of IMNN-101 showing proof of concept of the PlaCCine technology, demonstrating better durability of protection compared to ...

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Updated data from RUBY-3 ...

JADE101 is an investigational,potentially best-in-class disease-modifyinganti-APRIL monoclonal antibody, with a Phase 1 healthy volunteer study underway SAN FRANCISCO and VANCOUVER, British Columbia, ...

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on ...

The Texas-based company announced on Tuesday that its research collaborators will present preclinical data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin) at the ...